• Dapps:16.23K
  • Blockchains:78
  • Active users:66.47M
  • 30d volume:$303.26B
  • 30d transactions:$879.24M

BIO Protocol and NuDAO Join Forces to Accelerate Decentralized Science Development

user avatar

by Giorgi Kostiuk

a year ago


BIO Protocol and NuDAO have entered into a partnership aimed at strengthening the decentralized science ecosystem through strategic resource allocation and collaboration.

A Transformative Partnership

A recent press release announced NuDAO's strategic allocation of 6.9% of its treasury to BIO Protocol, highlighting a long-term collaboration to accelerate the decentralized science ecosystem. This partnership combines NuDAO's technological expertise in biotech and AI with BIO Protocol's established DeSci infrastructure.

This strategic partnership demonstrates our confidence in BIO Protocol’s vision and our shared commitment to advancing decentralized science.NuDAO

Key Elements of the Partnership

The partnership includes scientific and technical collaborations: * Joint Development: NuDAO and BIO Protocol will collaborate on significant scientific research initiatives, focusing on IP and NFT development. * Co-Incubation Projects: Both organizations will incubate promising research projects together, providing shared resources and expertise. * Governance: Both entities will actively participate in each other's governance frameworks, promoting collaboration and shared decision-making in DeSci development.

The Role of the CRISPR Token

A key component of the partnership is the integration of NuDAO's CRISPR token, which powers the research ecosystem. CRISPR will gain access to BIO Protocol’s research resources, driving innovation. CRISPR token holders will have the opportunity to participate in key decisions, influencing the future of decentralized science. The collaboration will enhance CRISPR’s position within the broader DeSci network, unlocking opportunities for growth and innovation.

The partnership aims to create a global decentralized research community enabling borderless collaboration. It supports the commercialization of biotech innovations, such as rare disease research and longevity research.

0

Rewards

chest
chest
chest
chest

More rewards

Discover enhanced rewards on our social media.

chest

Other news

Brian Ferdinand Recognized as Breakout Trader of the Year

chest

Brian Ferdinand has been recognized as Breakout Trader of the Year for achieving an impressive return exceeding 25% within the first two months of 2026.

user avatarGustavo Mendoza

Transforming Web3 AdTech: ChainAware and MelosClaw's Strategic Partnership

chest

The partnership is set to transform the Web3 advertising landscape by leveraging blockchain data for better targeting.

user avatarRajesh Kumar

ChainAware and MelosClaw Enhance Web3 Advertising Execution and Scalability

chest

ChainAware and MelosClaw are enhancing Web3 advertising execution and scalability through real-time data processing capabilities.

user avatarMaria Gutierrez

StakeStone's Ecosystem Developments Provide Context for Price Rally

chest

StakeStone is building a broader ecosystem narrative that includes a neobank model and a new governance structure.

user avatarLuis Flores

ChainAware and MelosClaw Join Forces to Revolutionize AI in Web3

chest

ChainAware and MelosClaw are collaborating to improve AI functionality in the Web3 ecosystem by integrating their technologies.

user avatarDavid Robinson

Surge in Trading Volume Confirms Strong Market Participation for StakeStone

chest

Surge in trading volume for StakeStone's STO token by over 660% indicates strong market participation.

user avatarMiguel Rodriguez

Important disclaimer: The information presented on the Dapp.Expert portal is intended solely for informational purposes and does not constitute an investment recommendation or a guide to action in the field of cryptocurrencies. The Dapp.Expert team is not responsible for any potential losses or missed profits associated with the use of materials published on the site. Before making investment decisions in cryptocurrencies, we recommend consulting a qualified financial advisor.